Cefuroxime Axetil Primary Use
Cefuroxime axetil is primarily used as an oral second-generation cephalosporin for treating community-acquired bacterial respiratory tract infections, including acute bacterial sinusitis, pharyngitis/tonsillitis, acute otitis media, and community-acquired pneumonia, as well as skin/soft tissue infections and urinary tract infections. 1
FDA-Approved Indications
According to the FDA drug label, cefuroxime axetil for oral suspension is specifically indicated for pediatric patients (3 months to 12 years) with mild to moderate infections caused by susceptible organisms 1:
- Pharyngitis/Tonsillitis caused by Streptococcus pyogenes
- Acute Bacterial Otitis Media caused by S. pneumoniae, H. influenzae (including beta-lactamase-producing strains), M. catarrhalis (including beta-lactamase-producing strains), or S. pyogenes
- Impetigo caused by S. aureus (including beta-lactamase-producing strains) or S. pyogenes
Primary Clinical Applications Based on Guidelines
Respiratory Tract Infections
Cefuroxime axetil is most commonly prescribed for respiratory tract infections, representing its principal clinical use 2, 3, 4, 5.
For acute bacterial sinusitis, cefuroxime axetil is recommended as first-line therapy alongside amoxicillin-clavulanate and certain third-generation cephalosporins 3. The guidelines specifically note that cefuroxime axetil has "significantly enhanced activity against β-lactamase-producing H. influenzae, M. catarrhalis, and S. aureus" with the advantage of twice-daily administration 2.
For community-acquired pneumonia in adults, cefuroxime axetil serves as part of combination therapy (β-lactam plus macrolide) for outpatients with comorbidities or risk factors for drug-resistant S. pneumoniae 6. The recommended regimen is cefuroxime 500 mg twice daily combined with a macrolide.
Early Lyme Disease
Cefuroxime axetil (500 mg twice daily for 14-21 days) is one of three first-line oral antibiotics for early localized or early disseminated Lyme disease associated with erythema migrans 7. It is equally effective as doxycycline and amoxicillin for this indication.
Acute Otitis Media
In pediatric patients, cefuroxime axetil is recommended for acute otitis media, particularly when β-lactamase-producing organisms are suspected 3, 8. However, the guidelines note that "cefuroxime axetil is unpalatable in suspension," which may limit adherence in young children 2.
Key Microbiological Coverage
Cefuroxime axetil's primary utility stems from its activity against the most common community-acquired respiratory pathogens 4, 9, 10:
- Streptococcus pneumoniae (including penicillin-susceptible and intermediate strains)
- Haemophilus influenzae (including β-lactamase producers)
- Moraxella catarrhalis (including β-lactamase producers)
- Streptococcus pyogenes
- Methicillin-sensitive Staphylococcus aureus
Important Clinical Caveats
First-generation cephalosporins like cephalexin have poor coverage for H. influenzae and are inappropriate for respiratory infections 2. Cefuroxime axetil, as a second-generation agent, overcomes this limitation.
The drug should not be used for penicillin-resistant S. pneumoniae with high-level resistance, as one report suggested worse outcomes when cefuroxime was used to treat pneumococcal bacteremia with resistant organisms 6.
Cefuroxime axetil tablets and oral suspension are not bioequivalent and cannot be substituted on a milligram-per-milligram basis 1. The suspension actually achieves higher drug exposure and can cover MICs up to 1.0 mg/L, compared to 0.5 mg/L for the 500 mg tablet 11.
The typical adult dosing is 250-500 mg twice daily, with the specific dose depending on infection severity and site 1, 4, 9. Treatment duration is generally 5-14 days for most respiratory infections, with shorter 5-day courses shown to be as effective as 10-day courses for certain indications 4, 9.